Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria
| Filename | 89. Metz et al.,Rupatadine and its effects on symptom,AAAI2010.pdf |
| Filesize | 772.24 KB |
| Version | o.089 |
| Date added | May 27, 2020 |
| Downloaded | 0 times |
| Category | Original Work |
| Authors | Metz, M., Scholz, E., Ferrán, M., Izquierdo, I., Giménez-Arnau, A., and Maurer, M. |
| Citation | Metz, M., Scholz, E., Ferrán, M., Izquierdo, I., Giménez-Arnau, A., and Maurer, M.: Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann. Allergy Asthma Immunol. 2010: 104; 86-92. IF: 2.80 |
| Corresponding authors | Maurer, M. |
| DocNum | O.89 |
| DocType | |
| Edition; Page | 104; 86-92 |
| IF | 2.80 |
| Publisher | Ann. Allergy Asthma Immunol. |
| ReleaseDate | 2010 |
Background: Patients with acquired cold urticaria (ACU) show itchy wheals during cold exposure. This disturbing condition involves histamine and platelet-activating factor in its pathogenesis. Rupatadine is a dual antagonist of both histamine and platelet-activating factor.
Objective: To assess rupatadine efficacy in preventing reactions to cold challenge in patients with ACU.
Methods: A crossover, randomized, double-blind, placebo-controlled study in which 21 patients with ACU received rupatadine, 20 mg/d, or placebo for 1 week each is presented. The main outcome was the critical stimulation time threshold (CSTT) determined by ice cube challenge. Secondary outcomes included CSTT and the critical temperature threshold assessed by a cold provocation device (TempTest 3.0), as well as scores for wheal reactions, pruritus, burning sensations, and subjective complaints after cold challenge.
Results: After rupatadine treatment, 11 (52%) of 21 patients exhibited a complete response (ie, no urticaria lesions after ice cube provocation). A significant improvement in CSTT compared with placebo was observed after ice cube and TempTest 3.0 challenge (P .03 and P .004, respectively). A significant reduction of critical temperature threshold (P .001) and reduced scores for cold provocation-induced wheal reactions (P .01), pruritus (P .005), burning sensation (P .03), and subjective complaints (P .03) after rupatadine treatment were also found. Mild fatigue (n 4), somnolence (n 1), and moderate headache (n 1) were reported during active treatment.
Conclusion: Rupatadine, 20 mg/d, shows high efficacy and is well tolerated in the treatment of ACU symptoms.
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.